Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103443 | 0.85 | TLR7 (0.36) | POLBKDM4ETLR7 | |
| SCHEMBL1103326 | 0.84 | TLR7 (0.35) | KDM4EGPR3TLR7BCHE | |
| SCHEMBL1103608 | 0.84 | POLB (0.35) | PDE10APOLBKDM4EGPR3MET | |
| SCHEMBL1103550 | 0.83 | MET (0.37) | KDM4EGPR3TLR7METBCHE | |
| SCHEMBL1103611 | 0.83 | MEN1 (0.37) | POLBKDM4EGPR3DHFRMET | |
| SCHEMBL1103612 | 0.83 | POLB (0.35) | PDE10APOLBKDM4EGPR3 | |
| SCHEMBL1103607 | 0.83 | BCHE (0.36) | PDE10APOLBKDM4EGPR3MET | |
| SCHEMBL1102819 | 0.79 | TNF (0.40) | POLBKDM4EDHFRBCHE | |
| SCHEMBL1103239 | 0.79 | GAA (0.34) | POLBKDM4EDHFR | |
| SCHEMBL1103603 | 0.76 | KDM4E (0.36) | PDE10AKDM4EGPR3DHFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | PDE10A 3477/4885POLB 2825/4885KDM4E 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.